Arylpiperazines having activity at the serotonin 1A receptor

Details Arylpiperazines having activity at the serotonin 1A receptor Arylpiperazines having activity at the serotonin 1A receptor

2006-02-21

2006-02-21

Richter, Johann (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S255030, C544S360000

Reexamination Certificate

active

07001908

ABSTRACT:
A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1Areceptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.

REFERENCES:
patent: 4536516 (1985-08-01), Harper et al.
patent: 4988814 (1991-01-01), Abou-Gharbia et al.
patent: 5292732 (1994-03-01), Rover
patent: 5340812 (1994-08-01), Cliffe
patent: 5346896 (1994-09-01), Ward et al.
patent: 5541326 (1996-07-01), Cliffe
patent: 5614523 (1997-03-01), Audia et al.
patent: 5693642 (1997-12-01), Cliffe et al.
patent: 6239135 (2001-05-01), Kohlman et al.
patent: 6358958 (2002-03-01), Kohlman et al.
patent: 637389 (1964-03-01), None
patent: 1076446 (1993-09-01), None
patent: 0512755 (1992-11-01), None
patent: 0521368 (1993-01-01), None
patent: 0661266 (1995-07-01), None
patent: 2248499 (1992-04-01), None
patent: 2303303 (1997-02-01), None
patent: WO 92/06082 (1992-04-01), None
patent: WO 92/06082 (1992-04-01), None
patent: WO 94/21610 (1994-09-01), None
Jones, Brian et al., The Medical benefit of 5-HT research, Pharmacology, Biochemistry and Behaviour 71 (2002), pp. 555-568.
Balducci et al., Psychopharmacology (Berl), Apr. 2003; 167(1):28-36 (Abstract Only).
Boast et al., Neurobiol Learn Mem, 1999; 71(3):259-71. (Abstract Only).
Buhot et al., Ann Med, Apr. 2000; 32(3):210-21. (Abstract Only).
Cassaday et al., Q J Exp Psychol B, Aug. 2000; 53(3):225-38. (Abstract Only).
Francis, P., Neurodegeneration, Dec. 1996; 5(4):461-5. (Abstract Only).
Harder et al., Psychopharmacology (Berl), Oct. 1996; 27(3):245-54. (Abstract Only).
Khalifa, A., J Ethnopharmacol; Jun. 2001; 76(1):49-57. (Abstract Only).
Lai et al., Brain Res, Jun. 2003; 974(1-2):82-7. (Abstract Only).
Meneses, A., Rev Neurosci, 1998; 9(4):275-89. (Abstract Only).
Misane et al., Neuropsychopharmacology, Feb. 2003; 28(2):253-64. (Abstract Only).
Pitsikas et al., Brain Res, Sep. 5, 2003; 983(1-2):215-22). (Abstract Only).
Schlechter et al., Curr Pharm Dec. 2002, 8(2):139-145.
European Search Report for European Application No. EP 04 07 8368, mailed Jan. 27, 2005.
Office Action from co-pending Canadian Patent Application No. 2,315,227, dated Apr. 19, 2004.
ID Patent Fast Alert, Jul. 1997, citing GB 2303303A.
Morren, H. et al., Industrie Chimique Belge. 28(2), 123 (1963).
Rasmussen, K. and V. Rocco, Annual Reports Med. Chem., 30(1), 1 (1995).
E. Diez-Barra et al., Tetrahedron, 53(33), 11437-11448 (1997).
E. C. Dodds et al., Proceedings of the Royal Society of London, Series B; Biological Sciences, 127, 140-167 (1939).
T. Kawabata et al., Journal of the American Chemical Society, 113(25), 9694-9696 (1991).
Chemical Abstracts, 115(26), Dec. 30, 1991, Abstract No. 280741k.
Heme, Hans-George, Justus Liebigs Annalen Der Chemie, 735, 56-64 (1970).
Saxena, Pramod R., Pharmac. Ther., 66, 339-368 (1995).
Robichaud et al., Annual Reports in Medicinal Chemistry, 11-20 (2000).

Affiliated with

Also associated with

Rating

Arylpiperazines having activity at the serotonin 1A receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Arylpiperazines having activity at the serotonin 1A receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylpiperazines having activity at the serotonin 1A receptor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3683202